CTCE 9908

Drug Profile

CTCE 9908

Alternative Names: CTCE-9908

Latest Information Update: 28 Sep 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Chemokine Therapeutics
  • Class Antineoplastics; Chemokines
  • Mechanism of Action CXCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 15 Mar 2007 Interim results from a phase Ib/II clinical trial in solid tumours added to the Cancer therapeutic trials section
  • 02 May 2006 Phase-Ib/II clinical trials in Solid tumours in Canada (IV)
  • 21 Feb 2006 Preclinical trials in Solid tumours in Canada (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top